Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic
July 9-11, 2024 | Boston, MA
Welcome to the 3rd In Vivo Cell Engineering & Gene Editing Summit!
As promising pre-clinical results continue to emerge, the shift from the βdreamβ of in vivo cell engineering and gene editing is rapidly becoming a reality, with numerous companies pushing towards the clinic.
The 3rd In Vivo Cell Engineering & Gene Editing Summit is showcasing the latest advances in preclinical development, IND-enabling studies, first clinical data readouts, and more, while also providing clarity on the full in vivo landscape.
This is your chance to unite with industry giants like Capstan Therapeutics, Editas Medicine, NanoCell Therapeutics, Carisma Therapeutics, Mustang Bio, iECURE, and many others, for exclusive access to groundbreaking discoveries and networking opportunities, propelling your pipelines to new heights!
Key Highlights
Exploring data-driven case studies to outline decision making when selecting viral versus non-viral vectorsΒ
Clarifying regulatory expectations for this novel therapeutic approachΒ to map out the future of your pipeline
Benchmarking appropriate preclinical models to support translationΒ to gain valuable data needed by regulatory bodies
Outlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks
Emphasizing target specificity and the mitigation of off-site toxicities to ensure safety is front of mind in development
Download the Full Agenda for More Information on:
-
-
-
- 15+ In Vivo Expert Speakers
- 2 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- & Much More!
-
-
World-Class Speaker Faculty Includes
Adrian Bot
Founding Chief Scientific Officer and Executive Vice President of R&D
Capstan Therapeutics
